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Cyanobacteria are one of the most widespread microorganisms on earth, and they
are found in almost all ecosystems, from fresh and marine water to terrestrial
environments. Cyanobacteria received a great deal of attention as prolific producers
of bioactive secondary metabolites. The aim of this study was to screen and
characterize novel bioactive natural products, which present biological activity
against acute myeloid leukemia (AML) cells, trypsin, and hepatotoxin
microcystin/nodularin, from cyanobacteria isolated from different habitats.
Of 40 cyanobacteria strains isolated from the Baltic Sea shore and lichen symbiosis
were used to look for anti-cancer compounds which could induce apoptosis of
AML cells. Half of these cyanobacteria strains contain apoptosis-inducing anti-
AML activity, and seven cell extracts contain potent apoptosis-induced activities
against AML. Two of apoptogens were confirmed to be new variants of hassallidin
and scytophycin.
Cyanobacteria produce a plethora of serine protease inhibitors with a broad range
of chemical structures. Nostosins, new trypsin inhibitors, were discovered through
the analysis of secondary metabolites in methanol extracts of Nostoc sp. FSN. The
data showed that they were linear peptides with three residues: Hhpba, L-Ile and L-
argininal/argininol. Nostosin A and B inhibited trypsin with IC50 values of 0.35 μM
and 55 μM, respectively. Computer docking data indicated that the argininal
aldehyde and guanidino groups played the most crucial role in the efficient
inhibition of trypsin.
The bloom-forming cyanobacterium Nodularia spumigena has been reported to
produce several bioactive peptides. In this study, Nodularia spumigena strains from
the Baltic Sea were discovered to produce new hybrid peptides named as
pseudoaeruginosins. Because of the low abundance in cyanobacteria strains,
pseudoaeruginosins were chemically synthesized and the structure was confirmed
with  LC-MS  and  NMR.  Pseudoaeruginosins  contained  all  the  structure  blocks  of
aeruginosin NAL2 except that the Choi was replaced by 4-methylproline (4-mPro),
which is a specific subunit of spumigins in N. spumigena. The aldehyde group
7containing pseudoaeruginosin NS1 exhibited IC50 of 0.19 μM against porcine
trypsin. The biosynthesis of pseudoaerugnosins was proposed to be a joint action of
aeruginosin and spumigin biosynthesis pathways in N. spumigena.
4-mPro is a rare non-proteinogenic amino acid, which has been found in a small
number of bioactive compounds identified from cyanobacteria. A combination of
PCR and LC-MS were used to screen 116 cyanobacteria strains for the production
of  4-mPro.  A  total  of  12  strains  were  confirmed  to  produce  4-mPro,  and  eleven
new cyclic peptides belonging to two groups were identified from two Nostoc spp.
XPORK 5A and UK2aImI strains, respectively. Among 11 peptides, the tested five
could inhibit the organic anion transporters OATP1B1/B3 to block the induction of
apoptosis of hepatocytes by microcystin/nodularin.
In this research, a total of two new trypsin inhibitors and five new cyclic peptides
with the antitoxic bioactivity against microcystin/nodularin were identified. It was
shown that cyanobacteria from both marine and terrestrial environments are a good
resource for discovering new bioactive compounds. These findings increased the
diversity of bioactive secondary metabolites characterized from cyanobacteria and
provide new leads for drug research.
81. Introduction
1.1 Cyanobacteria
Cyanobacteria are among the most successful microorganism on earth and were
most likely present since 2600 million years ago (Hedges et al. 2001). The
emergence of cyanobacteria is associated with the change of atmosphere from a
reductive to oxidative state (Blankenship and Hartman 1998; Summons et al. 1999).
Cyanobacteria are Gram-negative bacteria, which are the only bacteria capable of
performing oxygenic photosynthesis. They were regarded as algae, but finding the
typical bacterial cell structure finally led to their placement into prokaryotic
kingdom (Stanier et al. 1978). Cyanobacteria are adaptive microorganisms that
could be found almost all the ecosystems from terrestrial to aquatic habitats
including extreme environments such as hot springs, hypersaline environments and
glaciers (Garcia-Pichel et al. 1998; Papke et al. 2003; Comte et al. 2007).
1.2. Cyanobacterial secondary metabolites
With the emergence of antibiotic and chemotherapy resistance, more and more
medicines gradually lose their effect. In 2013, more than 2 million infections were
caused by antibiotic resistant bacteria, and 23 thousand people have died in US
(CDC report. 2013). There is an urgent need for new pharmaceuticals. Even though
more and more chemical libraries were built up for screening new drugs, the
natural products remain an important resource for drug leads (Cragg and Newman
2013). The screening of new drugs could be from many different sources, such as
plants, microbes and animals (Debnath et al. 2007; Jachak and Saklani 2007; Bah
et al. 2013; Gomes et al. 2014). Most of those bioactive natural products are
explored from plants and microbes (Berdy 2012). As one of the most successful
and ancient microorganisms, cyanobacteria have shown a great potential in drug
discovery (Singh et al. 2005; Tan 2007; Dixit and Suseela 2013).
Cyanobacteria have been considered as good resources to find novel bioactive
natural products, which are mostly from the secondary metabolites pool (Welker
9and von Döhren 2006; Sivonen and Börner 2008). The cyanobacterial secondary
metabolites present diverse chemical structure, and many of them show different
bioactivities, such as anti-cancer, anti-fungal, anti-bacteria, trypsin inhibitor,
neurotoxic and hepatotoxic (Singh et al. 2005; Dixit and Suseela 2013). Most of
these compounds are synthesized from the machinery of NPRS (non-ribosomal
peptide synthetase) or mixed with PKS (polyketide synthase) (Welker and von
Döhren  2006).  However,  some  of  them  are  from  ribosomal  pathways,  such  as
microviridins and cyanobactins (Arnison et al. 2013). The role of these natural
products is still not clear for the producers. They have been considered as potential
drug leads (Tan 2007; Dixit and Suseela 2013).
1.2.1. Anti-cancer compounds in cyanobacteria
Cyanobacteria are well-known to produce a number of anti-cancer compounds.
Many of these anti-cancer compounds target tubulin or actin filaments of
eukaryotic cells, such as cryptophycin, curacin A and dolastatin 10 (Figure 1).
Dolastatin 10 was first isolated from Dollabella auricularia, a species of large sea
slug (Figure 1) (Pettit et al. 1987), and found later in cyanobacterium Symploca sp.
(Luesch  et  al.  2001).  As  a strong microtubule inhibitor, dolastatin 10 can arrest
cells in mitotic division. Curacin A is an anti-cancer compound with a unique
chemical structure which includes a cyclopropyl-substituted thiazoline heterocyclic
ring  isolated  from Lyngbya majuscula (Figure 1).  It  is  a  strong  antiproliferative
agent that inhibits microtubule assembly (Gerwick et al. 1994). Cryptophycin is an
effective anti-fungal depsipeptide identified from Nostoc sp. GSV 224 (Schwartz et
al. 1990). Later, it was proven that cryptophycin was a good cytotoxic agent
against L1210 leukemia cells, the ovarian carcinoma and drug resistant breast
cancer cells (Smith et al. 1994; Trimurtulu et al. 1994). A number of cryptophycin
analogues were synthesized, the most potent of which is the cryptophycin 52,
which has one methyl group on the C-terminal residue comparing with
cryptophycin A (Figure 1), which binds the microtubule ends to disturb the cell
mitosis (Panda et al. 1998).
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Figure 1. The chemical structures of cryptophycin 52, curacin A, and dolastatin 10,
all well studied anti-cancer compounds from cyanobacteria (Pettit et al. 1987;
Gerwick et al. 1994; Wagner et al. 1999).
Acute myeloid leukemia is one of the cancers with the characteristics of fast-
growing  abnormal  white  blood  cells  in  the  bone  marrow.  Until  now,  there  is  no
very effective and safe treatment for this special disease. The common strategy is to
use chemotherapy to kill the leukemia cells (Mehta and Hoffbrand 2010). However,
the increasing trend of drug resistance has limited utility of anti-AML drugs
(August et al. 2013; Craddock et al. 2013). Nowadays, marine cyanobacteria are
emerging as new source to find bioactive natural products. Many new cytotoxic
compounds against cancer cells were found from marine cyanobacteria, especially
from Lyngbya spp. (Tan 2007). However, there is only one study which has
explored anti-leukemia compounds from marine cyanobacteria. Oftedal et al. (2010)
reported many cyanobacteria isolates from Baltic Sea contained anti-leukemia
activity (Oftedal et al. 2010). Therefore, it is necessary to make use of marine
cyanobacteria to find more effective anti-leukemia compounds in order to meet the
increasing need of medicine in the treatment of leukemia diseases.
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1.2.2. Trypsin inhibitors in cyanobacteria
As  one  member  of  protease  family,  trypsin  has  been  shown  to  play  an  important
role in a variety of cancers or brain development. The trypsin-like protease (or
called trypsinogen) has been found in many types of carcinomas, such as ovarian
neoplasm, pancreatic cancer, lung neoplasm and colorectal cancers (Nyberg et al.
2006). The high level of tumor-associated trypsinogen 2 is able to cause increased
occurrence  of  tumors  (Koivunen  et  al.  1990).  In  the  brain,  trypsin  IV  has  shown
wide distribution. Through the activation of PAR (protease-activated receptors)-1
or PAR-2, trypsin IV could perform neuroprotection from toxic insults in the brain
(Wang et al. 2008). In addition, trypsin IV also proposed to contribute on
neurogenic inflammation and pain by inducing PAR-2-dependent hyperalgeisia to
thermal and mechanical stimuli (Wang et al. 2008). Therefore, trypsin or trypsin-
like protease could be used as a good target to design new drugs, and trypsin
inhibitors will be one of the idea drug leads.
As the good resources for looking for new natural products, cyanobacteria have
been shown to synthesize a variety of trypsin inhibitors with diverse chemical
structures (Table 1). Among them, aeruginosins are one of the best-known trypsin
inhibitors discovered from cyanobacteria. Up to now, more than 55 variants have
been  studied  (Ersmark  et  al.  2008,  Liu  et  al.  2014),  and  some  new  variants  have
been uncovered recently by Fewer et al. (2013). The biosynthetic gene cluster was
first elucidated by Ishida et al. (2007). The aeruginosin gene cluster is composed of
9  genes.  There  are  one  PKS  and  two  NRPS,  which  are  responsible  for
incorporation of the subunits of aeruginosin 126 (Figure 2). Another group of
linear trypsin inhibitors, spumigins, was also discovered from cyanobacteria (Fujii
et al. 1997; Fewer et al. 2009; Anas et al. 2012; Mazur-Marzec et al. 2013). The
biosynthesis gene cluster of spumigin was identified by Fewer et al. (2009). There
are six genes in the cluster (Figure 2). The genes of spuA and spuB code for two
non-ribosomal peptide synthetases, which are responsible for synthesis of spumigin
E, a potent trypsin inhibitor. In addition, spuD and spuE show more than 90%
identity to nosE and nosF genes, which code two enzymes, a zinc-dependent long-
12
chain dehydrogenase and a Δ1-pyrroline-5-carboxylic acid (P5C) reductase (Luesch
et al. 2003; Fewer et al. 2009).
Figure 2. The biosynthesis gene clusters of aeruginosin 126 and spumigin E
(Ishida et al. 2007; Fewer et al. 2009).
Cyanobacteria were shown to synthesize other trypsin inhibitors, such as
microphycin AL828, A90720A, pompanopeptins, planktocyclin, banyasides and
symplocamide A (Figure 3 and Table 1). Even though they show diverse chemical
structures, they all have the same bioactivity. In order to study how the
cyanobacteria trypsin inhibitor interact with trypsin, aeruginosin 98-B was
cocrystallized with trypsin (Sandler et  al.  1998).  It  was shown that Ser195, His57
and Asp102 in trypsin form strong interaction with the corresponding sites on
aeruginosin 98-B. Because of the potent bioactivity and clear functional
mechanism, aeruginosin 98-B was utilized as a lead structure to design new
thrombin inhibitors used in the treatment of thrombosis (Radau et al. 2003).
Besides trypsin inhibitors, cyanobacteria are also well-known to produce other
protease inhibitors, such as the inhibitors of chymotrypsin, elastase, cathepsin,
leucine and aminopeptidase (Table 1).
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Figure 3. Examples of the trypsin inhibitors discovered from cyanobacteria.
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Table 1. Protease inhibitors discovered from cyanobacteria show diverse bioactivities and structures. M: monoisotopic
mass.
Protease inhibitor Cyanobacterial strain M (Da) Inhibitor against Reference
Spumigin E Nodularia spumigena 610 trypsin Fewer et al. 2009
Aeruginosins 98A Microcystin aeruginosa 687 trypsin Murakami et al. 1995
Microphycin AL828 Microcystis sp. 828 trypsin Gesner-Apter and Carmeli 2008
A90720A Microchaete loktakensis 1040 trypsin Bonjouklian et al. 1996
Pompanopeptins Lyngbya confervoides 1069 trypsin Matthew et al. 2008
Planktocyclin Planktothrix rubescens 800 trypsin/chymostrypsin Baumann et al. 2007
Banyasides A Nostoc sp. 990 trypsin/thrombin Pluotno and Carmeli 2005
Symplocamide A Symploca sp. 1050 trypsin/chymostrypsin Linington et al. 2008
Micropeptin MM836 Microcystis sp. 836 chymostrypsin Zafrir-Ilan and Carmeli 2010
Cyanopeptolin 954 Microcystis aeruginosa 954 chymostrypsin von Elert et al. 2005
Anabaenopeptin MM823 Microcystis sp. 823 chymotrypsin/elastase Zafrir-Ilan and Carmeli 2010
Molassamide Dichothrix utahensis 962 chymotrypsin/elastase Gunasekera et al. 2010
Oscillapeptin A Oscillatoria agardhii 1165 chymotrypsin/elastase Shin et al. 1995
Largamide A Lyngbya confervoides 841 elastase Matthew et al. 2009
Scyptolin A Scytonema hofmanni 980 elastase Matern et al. 2001
Kempopeptins A Lyngbya sp. 990 elastase Taori et al. 2008
Microviridin G Nostoc minutum 1805 elastase Murakami et al. 1997
Grassypeptolide A Lyngbya confervoides 989 protease Kwan et al. 2014
Lyngbyastatin 5 Lyngbya sp. 1056 protease Taori et al. 2007
Gallinamide A Schizothrix sp. 592 cathepsin Miller et al. 2014
Grassystatin A Lyngbya cf. confervoides 1174 cathepsin Kwan et al. 2009
Microginins 299-C/D Microcystis aeruginosa 852/756 leucine aminopeptidase Ishida et al. 1998
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1.2.3. Bioactive compounds with 4-methylproline in cyanobacteria
The 4-mPro is a special non-proteinogenic amino acid, in which the methyl group
is connected to the second carbon of the side chain. In cyanobacteria, it was
discovered in nostopeptolide A and nostocycleopeptide A (Golakoti et al. 2000;
Golakoti et al. 2001). However, both of these compounds showed no bioactivity
during the discovery. The biosynthesis of 4-mPro has been revealed by Luesch et al.
(2003). A zinc-dependent long-chain dehydrogenase and a Δ1-pyrroline-5-
carboxylic acid (P5C) reductase, which are coded by genes nosE and nosF in
Nostoc sp. GSV 224, convert L-Leu in to 4-mPro. Later on, 4-mPro biosynthetic
genes were also found in the biosynthetic gene cluster of nostocycleopeptin A in
Nostoc sp. ATCC 53789, nostopeptolide A in Nostoc sp. GSV 224, nostopeptolide
in Nostoc punctiforme PCC 73102 and spumigin E in Nodularia spumigena
CCY9414 (Figures 4 and 5) (Hoffmann et al. 2003; Becker et al. 2004; Hunsucker
et al. 2004; Fewer et al. 2009).
Figure 4. The biosynthetic gene clusters of 4-mPro-containing compounds
discovered in cyanobacteria (Hoffmann et al. 2003; Becker et al. 2004; Hunsucker
et al. 2004; Fewer et al. 2009).
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The end products of these four gene clusters were also identified, but only
spumigin E was shown to be a strong trypsin inhibitor (Fewer et al. 2009), while no
biological activity were reported to the other three compounds.
Figure 5. Examples of 4-mPro-containing compounds isolated from cyanobacteria.
17
HO
O
O
N
H
O
OH
O
H
N
O
OR
HN
O
N
N
OH
OH
O
NH
NH
O
HO
O
H
N
O
HN
O
NH
O
OH
N O
NH
O
Scytonemin A
N
O
N
H
O
O
NH
O HN
H
N
O
O
H
N
O
N
NO
NH2
O
O
OH
OCH3
Insulapeptolide D
In addition to 4-mPro, some other forms of methylproline have been discovered
from the natural peptides produced from cyanobacteria, such as 3-OH-4-mPro, 4-
OH-3-mPro and 3-mPro (Table 2 and Figure 6) (Helms et  al.  1988;  Okino  et  al.
1997).  3-mPro  was  first  found  in  scytonemin  A.  It  is  a  cyclic  peptide  with  a
molecular mass 1462, which was found from cyanobacteria strain Scytonema sp.
U-3-3. It contains one 3-mPro and two 4-OH-3-mPro (Helms et al. 1988). Though
scytonemin A was discovered very early, its biosynthetic gene cluster has not been
revealed. The 3-OH-4-mPro was explored from nostopeptins and insulapeptolides,
which are elastase inhibitors (Figure 6) (Okino et al. 1997; Mehner et al. 2008).
Both of them have a cyclic ring and a short branch chain. Besides the great
difference on the side chain, the ring structures are almost the same.
Figure 6. The chemical structures of scytonemin A, nostopeptin A and
insulapeptolid D. (Helms et al. 1988; Okino et al. 1997; Mehner et al. 2008)
18
Methylproline amino acids were also found in natural products such as bottromycin
D, perthamide, pteratides and leucinostatins synthesized by sponges, fungi and
actinobacteria (Table 2). Bottromycin D is a new anti-bacterial compound
produced by Streptomyes spp. (Hou et al. 2012). Hou et al. (2012) used both
structure and genome sequences to obtain its biosynthesis gene cluster. In
cyanobacteria, the 4-mPro was synthesized by two enzymes, which are A zinc-
dependent long-chain dehydrogenase and a Δ1-pyrroline-5-carboxylic acid (P5C)
reductase (Luesch et al. 2003). The biosynthesis of methylproline in bottromycin is
different from 4-mPro in cyanobacteria, because its methyl group is added by
methyltransferase (Hou et al. 2012). The data revealed new source of methylproline
amino acids.
19
Table 2. Methylproline-containing compounds isolated from cyanobacteria, sponges and other microbes.
Name Strain Bioactivity mPro type Reference
Scytonemin A Scytonema sp. calcium antagonistic property 3-mPro Helms	et	al.	1988		
Bottromycin D Streptomyces spp. anti-bacteria 3-mPro Hou	et	al.	2012	
Nostopeptins A/B Nostoc minutum anti-elastase/chymotrypsin 3-OH-4-mPro Okino	et	al.	1997		
Insulapeptolide A/B/C/D Nostoc insulare anti-elastase 3-OH-4-mPro Mehner	et	al.	2008		
Spumingin G/469/582/652* Nodularia spumigena - 4-mPro Mazur-Marzec	et	al.	
Spumingin E Nodularia spumigena anti-trypsin inhibitor 4-mPro Fewer	et	al.	2009		
Spumingin J Anabaena compacta anti-thrombin/cathepsin 4-mPro Anas	et	al.	2012	
Spumigin A/B Nodularia spumigena - 4-mPro Fujii	et	al.	1997	
Nostocylopeptide A1/A2 Nostoc sp. - 4-mPro Golakoti	et	al.	2001		
Nostocyclopeptide M1 Nostoc sp. antitoxin against microcystin 4-mPro Jokela	et	al.	2010	
Enopeptin A Streptococcus hawaiiensis anti-bacteria 4-mPro Hinzen	et	al.	2006		
Perthamide C/D Theonella swinhoei anti-inflammatory 4-mPro Festa	et	al.	2009		
PteratidesI/ II Pterula sp. anti-leukemia 4-mPro Chen	et	al.	2006		
Bisebromoamide Lyngbya sp anti-protein kinase 4-mPro Teruya	et	al.	2009		
Perthamide B Theonella sp. anti-1L-1b 4-mPro Gulavita	et	al.	1994		
Perthamide G-K Theonella swinhoei anti-inflammatory 4-mPro Festa	et	al.	2012		
Mutremdamide A Theonella species Peptide Inhibitors of HIV-1 4-mPro Plaza	et	al.	2010		
Perthamide E/F Theonella swinhoei anti-TNFa/IL-8 4-mPro Festa	et	al.	2011	
Nostopeptolide A1/A2/A3 Nostoc sp. - 4-mPro Golakoti	et	al.	2000		
Leucinostatins A/B Paecilomyces lilacinus anti-bacteria/fungi/cancer 4-mPro Fukushima	et	al.	1983	
*: the methylproline amino acids in the compound have not been confirmed to be 4-methylproline or methylproline.
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2. The aim of study
1.  To screen benthic (and planktic) cyanobacteria from coastal environments and
lichen symbiotic cyanobacteria for natural products with acute myeloid leukemia
apoptosis-inducing activity (paper I)
2. To identify new trypsin inhibitors from cyanobacteria isolated from terrestrial
and brackish water habitats with NMR and LC-MS (papers II, III).
3. To study the biosynthesis of pseudoaeruginosins in the bloom-forming
cyanobacterium Nodularia spumigena (paper III).
4. To find new bioactive compounds containing 4-mPro from cyanobacteria. The
structure and functional mechanism of new natural products were also in the study
focus (paper IV).
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3. Materials and Methods
The material and methods are described in detail in the four articles I-IV. A list of
methods used in this study is shown in Table 3.
Table 3. The methods used in the thesis.
Methods Paper
Mass cultivation of experimental cyanobacteria strains I, II, III, IV
Isotope labeling experiment with 15N and 34S II, V
PCR I, III, IV
16S rRNA gene sequencing I, IV
HPLC purification II, III, IV
LC-MS analysis I, II, III, IV
High resolution UPLC-ESI-QTOF mass spectrometry II, III, IV
NMR II, III, IV
Optical rotation II
Infrared spectroscopy II
UV spectrum measurement II
Organic synthesis III
Amino acid feeding experiment III
Chiral analysis of amino acid II, III, IV
Trypsin inhibition test II, III
Microcystin apoptosis-inducing experiment I, IV
Adenosine apoptosis-inducing experiment I
The screening of apoptosis-inducing activity against IPC-81 cells I
Green fluorescence protein expression IV
The inhibition of protein OATP1B1/1B3 mediated transport of
microcystin
I,IV
Computational docking analysis II
Bioinformatic analysis IV
22
4. Results and Discussion
4.1. Apoptogens against AML in cyanobacteria
Marine cyanobacteria have been shown to be a good resource to find anti-cancer
compounds (Tan 2007; Dixit and Suseela 2013). In this research, forty
cyanobacterial strains isolated from coastal, benthic and lichen-symbiotic
environments were utilized to explore new anti-AML compounds. All the
cyanobacteria strains were freeze dried and extracted with water, methanol and
dichloromethane at the rate of 1:1:1. After the centrifugation, the upper layer
(aqueous extracts) and lower layer (organic extracts) were separated and used in
the cell apoptosis-inducing experiments. More than half of these strains contained
the apoptosis-inducing activity (Figure 7).
Figure 7. Leukemia cell death induced by cyanobacteria extracts. IPC-81 (the cell
line IPC-81, isolated from brown Norwegian acute myelocytic leukemia rats) cells
were  incubated  with  extracts  from  5  mg  biomass/ml  cell  suspension  for  24  h
23
before fixation in 2% buffered formaldehyde (pH 7.4). The X-axis gives the strain
numbers. Cell death was assessed by microscopic assessment of the cell surface
and nuclear morphology. The horizontal lines show 30% (low) and 70% (high)
apoptosis levels.
Cyanobacteria are well-known producers of microcystin or nodularin,
hepatotoxins common especially in cyanobacterial blooms; (Dittmann and
Wiegand 2006; Sivonen 2009). More recently, they were found in terrestrial
environment in lichen symbiotic cyanobacteria (Oksanen et al. 2004; Kaasalainen
et al. 2012). Adenosine, which has been proven to be effective against leukemia
cells in vitro (Tanaka et al. 1994), is often found in aquatic extracts of freeze-dried
cyanobacteria cells. Here a new experimental strategy was used to exclude
adenosine and microcystins/nodularins in order to increase the efficiency of
finding new anti-AML compounds. The cyanobacterial cell extracts, which were
treated with adenosine deaminase, were used to induce the apoptosis of AML cells.
Both LC-MS and microcystin-inducing apoptosis experiment were introduced to
test the existence and amount of microcystins in the cyanobacterial cell extracts. It
was shown that many lichen-symbiotic cyanobacterial strains contain a large
amount of microcystins, and adenosine (Table  4 and Figure 8). Those strains
producing adenosine and high amounts of microcystin received more concern
during the screening, because it was not clear whether new apoptogens or
microcytin/adenosine lead to the apoptosis of leukemia cells.
Figure 8. The presence of adenosine or deaminase-sensitive compounds in
cyanobacterial extracts.
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Table 4. The presence of microcystin and microcystin-like activity in selected
cyanobacteria extracts.
Extract Strains Habitats
Microcystin-like activity
in OATP-transfected
HEK293 cells
Microcystins by
LC-MS (nM)
L1-A Calothrix HAN 24/1 Marine − −
L7-A Calothrix HAN 24/1 Marine − 3.9
L19-A Nodularia HAN 37/1 Marine − −
L20-A Calothrix HAN 16/1 Marine − −
L26-A Anabaena HAN 21/1 Marine − −
L30 A Nostoc 113.5 lichen- ND 3.8
L31-A Nostoc UK 92Ic lichen- + 2100
L32-A Nostoc UK 89 lichen- ++ 2700
L33-A Nostoc UK 81I lichen- + 5100
L35-A Nostoc UK 60II lichen- / 2600
L36-A Nostoc N135.9.1 lichen- − 620
L37-A Nostoc N138 lichen- + 13,000
L38-A Nostoc UK 104 lichen- − 54
L39-A Nostoc UK 220Ib lichen- + 2200
L40-A Nostoc N134.1 lichen- + 1300
L1-O Calothrix HAN 24/1 Marine − −
L10-O Calothrix HAN 21/5 Marine − −
L19-O Nodularia HAN 37/1 Marine − −
L25-O Anabaena HAN 15/2 Marine − −
L26-O Anabaena HAN 21/1 Marine − −
L32-O Nostoc UK 89 lichen- − 43
L33-O Nostoc UK 81I lichen- − 89
L38-O Nostoc UK 104 lichen- − 5.6
The + signifies the presence of bioactivity-inducing microcystin-like apoptotic morphology in
OATP1B3-transfected HEK293 cells (second column) or the detection of microcystin or nodularin by
LC-MS (third column). +, present, but less than 30% apoptosis; ++, strong (30%–100% apoptosis); −,
absent; /, unknown; ND = not determined due to necrotic morphology.
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It was reported that many cyanobacterial stains isolated from Baltic Sea contained
anti-leukemia activity, but no new natural products were reported (Oftedal et al.
2010). In this study, seven cell extracts showed good potential against leukemia
cells, some of them can even overcome the chemoresistance caused by regulated
proteins p53 (tumor suppressor) and Bcl-2 (B-cell lymphoma-2) (Table 5).
Table 5. The involvement of the chemotherapy resistance gene Bcl-2 and p53 in
apoptosis caused by potent cyanobacteria extracts. A comparison of the EC50 (half
maximal effective concentration) values of potent cyanobacterial extracts against
IPC-81 and Molm-13 cell lines.
Extract	 Strains	
EC50		
(IPC-81)	
Bcl-2	a	 p53	b	
EC50		
(Molm-13)	L19-A	 Nodularia HAN 37/1
	
2.4	 -	 0	 2.1	L26-A	 Anabaena HAN 21/1
	
>3.1	 -	 0	 >3.1	L30-A	 Nostoc 113.5
	
0.8	 -	 -	 <0.5	L36-A	 Nostoc N135.9.1
	
>4.8	 -	 0	 >4.8	L1-O	 Calothrix HAN 24/1
	
0.3	 -	 -	 <0.3	L26-O	 Anabaena HAN 21/1
	
<0.3	 +	 0	 <<0.3	L30-O	 Nostoc 113.5
	
ND	 +	 ND	 ND	
a -, extract not able to overcome resistance from Bcl-2; +, extract induces cell death also in
cells overexpressing Bcl-2; b 0, no change in cell response dependent on the p53 status; −,
absence of p53 protects cells from cyanobacterial extract; +, absence of P53 sensitizes cells to
cyanobacterial extract; ND, not determined.
The active apoptogens in these positive cell extracts were also studied (Table 4).
The hassallidins were firstly discovered as antifungal compound against fungi
Aspergillus fumigatus and Candida albicans (Neuhof et al. 2005). The new
hassallidin variants were identified from Nostoc sp. 113.5 (L30) with LC-MS, and
its biosynthesis genes were previously confirmed with PCR (Vestola et al. 2014).
Scytophycins are well-known natural products with antifungal and cytotoxic
activity. They were first identified from Scytonema pseudohofmanni (Ishibashi et
al. 1986). Here, the new variant of scytophycins was found from Anabaena sp.
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Han 21/1(L26). All these data indicated that the antifungal compounds identified
in cyanobacteria might be a good resource to find new anti-cancer activities.
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4.2. Nostosins-trypsin inhibitors
A pair of new trypsin inhibitors, nostosin A/B, was discovered from Nostoc sp.
FSN. The nostosins were obtained using RP-HPLC with the guide of LC-MS. The
MS, NMR and amino acid analysis showed they are composed of three residues,
Hhpba, L-Ile, and L-argininal/argininol (Figure 9).
Figure 9. Chemical structures of nostosin A and nostosin B.
Nostosins inhibited porcine trypsin with an IC50 (half minimal inhibitory
concentration)  value  of  0.35  µM  (nostoin  A)  and  55  µM  (nostosin  B).  Besides
nostosins, many trypsin inhibitors containing the characterized subunit arigninal
were identified, such as spumingin E, aeruginosin 102A, leupeptin, aeruginosin
89A (Table 6) (Aoyagi et al. 1969; Matsuda et al. 1996; Ishida et al. 1999; Fewer
et al. 2009). All of them are potent trypsin inhibitors, which show an IC50 below
0.6 µM. However, some other trypsin inhibitors without argininal from
cyanobacteria,  such  as  aeruginosin  205A/B,  also  inhibit  trypsin  with  a  low  IC50
(Table 6).
This indicates that other subunits or whole structure of compounds are also
important in trypsin inhibition. The cyanobacterial trypsin inhibitor, aeruginosin
98-B (argininol), was crystallized with trypsin together in order to study how linear
trypsin inhibitor binds to the activity pocket of trypsin (Sandler et al. 1998).
However, it is not clear how argininal interacts with trypsin.
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Table  6. The potent linear trypsin inhibitors identified in cyanobacteria and
actinomycete. They show an IC50 under 0.6 µM.
Name	 1	 2	 3	 4	
IC50	
(uM)	
Reference	
aeruginosin	205A	 L-Pla	 D-Cleu	 L-Choi-Xyl-S	 Agma	 0.09	 Shin	et	al.	1997	aeruginosin	205B	 D-Pla	 L-Cleu	 L-Choi-Xyl-S	 Agma	 0.09	 Shin	et	al.	1997	leupeptinΔ	 Ac	 L-Leu	 L-Leu	 L-Argal	 0.5	 Aoyagi	et	al.	1969	aeruginosin	89A	 D-Hpla-Cl-S	 D-Leu	 L-Choi	 L-Argal	 0.56	 Matsuda	et	al.	1996	aeruginosin	102A	 D-Hpla-S	 D-Tyr	 L-Choi	 L-Argal	 0.27	 Ishida	et	al.	1999	spumigin	E	 D-Hpla	 D-Hty	 L-mPro	 L-Argal	 <0.1	 Fewer,	et	al.	2009	
Ac	=	acetyl,	Argal	=	argininal,	Agma	(agmatine)	=	4-amidinobutylamide,	Cleu	=	3-chloro-Leu,	Choi	=	2-carboxy-6-hydroxyoctahydroindole,	Choi-Xyl-S	 =	Choi-6-O-(4-O-sulfate-xylose),	Hpla-Cl-S	 =	O-sulfated-m-chloro-Hpla,	 Hpla-S	 =	 O-sulfated-Hpla,	 Pla	 =	 phenyllactic	 acid.	 Δ:	 leupeptin	 was	 identified	 in	actinomycete.	
The nostosins A showed far more potent activity than nostosin B. These two
inhibitors have a very similar structure and differ only at the third residue, which is
argininal in nostosin A, and argininol in nostosin B (Figure  9). The argininal
residue seems to be crucial for trypsin inhibition. Similar results were also reported
in case of spumigins A and E (Fewer et  al.  2009).  The compounds of aeruginosin
89  A  and  B  show  that  also  the  configuration  of  argininal  is  important  so  that  L
configuration in argininal makes the compound an efficient trypsin inhibitor (Ishida
et al. 1999). In order to gain insight into nostosins inhibition mechanism,
computational docking of nostosins with trypsin was carried out (Figure 10).
As the stereochemistry of Hhpba was not proven, two configuration of Hhpba was
used to make computer docking of nostosins. From the docking prediction,
nostosin A in D-L-L configuration binds in a similar manner to leupeptin, which is
potent trypsin inhibitor discovered from actinomycetes (Aoyagi et al. 1969;
Kurinov and Harrison. 1996).
29
Figure 10. Binding poses of nostosins A and B, spumigin E and leupeptin. (A)
Most  favorable  binding  orientation  of  nostosin  A  in  the  binding  site.  (B)  Most
favorable binding orientation of nostosin B in the binding site. (C) Most favorable
binding orientation of spumigin E in the binding site. (D) Most favorable binding
orientation of leupeptin in the binding site (carbon atom labeled with black) and
extracted from the X-ray crystal structure with trypsin (protein data bank code: 1jrs;
carbon atom labeled with green).
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The  argininal  of  nostosin  A  and  leupeptin  could  form  covalent  bond  with  serine
Ser195.  In  nostosin  B,  the  argininal  was  replace  with  argininol,  therefore  the
absence of covalent bond prevents strong binding of nostosin B to the activity
center of trypsin. In addition, the guanidino group of nostosins forms an ion-pairing
with Asp189 and two strong hydrogen bonds with Ser190 and Gly219. These
noncovalent bonds, which happen in the S1 selectivity pocket in trypsin, strengthen
the inhibition on the trypsin.
31
4.3. Pseudoaeruginosins-trypsin inhibitors
Nodularia spumigena is a filamentous cyanobacterium, which could fix nitrogen. A
few bioactive compounds have been found from Nodularia sp. such as spumigins,
aeruginosins, nodularins (Fujii et al. 1997; Fewer et al. 2009; Fewer et al. 2013). In
this study, the structures of pseudoaeruginosins NS1 and NS2 are similar to the
new discovered trypsin inhibitor, aeruginosin NAL2/NOL3, with only difference
that the Choi was replaced with 4-mPro (Figure 11). It means pseudoaeruginosins
might come from aeruginosin biosynthesis pathway.
Figure 11. Aeruginosins and spumigin produced by strains of Nodularia
spumigena isolated from brackish water bodies in Australia and the Baltic Sea. (A)
aeruginosin NAL2, (B) methylproline-containing aeruginosin NS1, (C) spumigin E.
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Figure 12. The peak areas from the extracted ion chromatograms of the protonated
compounds of aeruginosins and spumigins. a = no detectable levels of aeruginosins,
b = no detectable levels of mPro containing spumigins, c = no detectable levels of
Pro containing spumigins, AUS = Australian strains.
In order to check the distribution of pseudoaeruginosins in the Nodularia
spumigena, a  total  of  68 N. spumigena strains collected from Baltic Sea and
Australia were screened to find pseudoaeruginosins.  A total of 33 strains showed
production of pseudoaeruginosins, but the others contain no pseudoaeruginosins or
the amount is  too low to detect (Figure 12). It was found that pseudoaeruginosin
successfully synthesized by those cyanobacteria strains which could produce a
large amount of aeruginosin and mPro-spumigin. On the right panel of Figure 12,
the production of mPro-supmigin is so low that the cyanobacteria strains have not
enough 4-mPro as substrate for the synthesis of pseudoaeruginosin. These findings
suggest that the spumigin biosynthesis pathway is involved in the synthesis of
pseudoaeruginosins by providing 4-mPro to the aeruginosin synthetase.
Spumigins  and  aeruginosins  were  reported  to  have  their  own  NRPS  pathway.  In
Nodularin spumigena CCY9414, no other biosynthetic gene clusters, which code
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for peptides resembling pseudoaeruginosin were discovered from this strain
(Fewer et al. 2009; Fewer et al. 2013). This suggests that pseudoaeruginosins are
produced through the joint action of spumigin and aeruginosin biosynthesis
pathways. This is first time in cyanobacteria to discover that two NRPS
biosynthesis pathways function together to assemble new metabolites (Figure 13).
Spumigin biosynthesis is most likely responsible for producing mPro for spumigin
and pseudoaeruginosin biosyntheses. Some of the 4-mPro is proposed here to be
activated by the AerG adenylation domain of aeruginosin synthetase leading to the
incorporation of 4-mPro into the growing pseudoaeruginosin chain. It has been
reported that NRPS of naphthyridinomycin and quinocarcin incorporate
hydroxyethyl C2 from central metabolic ketosugars by transketolases in
Streptomyces lusitanus (Peng et al. 2012).  This  is  an  example  of  joint  work
between central metabolites and NRPS biosynthesis pathway.
Figure 13. The proposed interaction between spumigin and aeruginosin
biosynthetic pathways leading to the formation of pseudoaeruginosin NS1 and NS2.
spuD and spuE are genes for 4-mPro synthesis, spuC function is unknown  and
aerD, aerE and aerF genes are for Choi synthesis (Fewer et al. 2009 and 2013).
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Abbreviations: A, adenylation domain; ACP, acyl carrier protein; C, condensation
domain; PCP, peptidyl carrier protein; KR, keto reductase domain; E, epimerase
domain; R, reductase domain.
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4.4. Nostoweipeptins and nostopeptolides-antitoxins against microcystin
In cyanobacteria, the biosynthesis of the non-proteinogenic amino acid 4-mPro was
first revealed by Luesch and coworkers (Luesch et al. 2003). Two genes, nosE and
nosF, were confirmed to code two enzymes that are responsible for converting
leucine to 4-mPro. In this study, genes nosE and nosF were used to find new gene
clusters possibly coding for 4-mPro-containing compounds. The gene clusters
examined came from national center for biotechnology information (NCBI) public
genome database. Finally, eight gene clusters containing 4-mPro biosynthetic genes
were found (Figure 14).
Figure 14. The gene clusters of 4-mPro containing-compounds in cyanobacteria
were blasted from national center for biotechnology information public
cyanobacteria genome database.
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In these gene clusters, 4-mPro genes have conserved distribution with open reading
frame (orf) and one ATP-binding cassette transporter (ABC transporter) (Figure
14). Therefore, it is possible to make use of methylproline genes to screen new
natural products from cyanobacteria with PCR. Even though only eight gene
clusters  with  4-mPro  genes  were  found,  it  does  not  mean  that  4-methylproline
genes are rare in cyanobacteria since only limited genome data is available.
In  order  to  explore  more  compounds  with  4-mPro  amino  acid  and  check  the
distribution of 4-mPro in cyanobacteria, 116 cyanobacteria strains were screened
with a combination of PCR and LC-MS (Figure 15).
Figure 15. PCR screening of 4-mPro biosynthetic genes from 116 cyanobacterial
strains, and LC-MS analysis of the presence of 4-mPro in the PCR positive strains.
The  4-mPro  genes  were  found  from  genus  of Anabaena, Nostoc, Fischerella and
Scytonema. Most of the 4-mPro owners are from Nostoc sp. The frequency of 4-
mPro genes in Anabeana sp.  is  low.  Based  on  the  screening  results,  the  4-mPro
genes are not rare in cyanobacteria, especially in Nostoc strains.  A  total  of  12
producers of 4-mPro were found. With the guidance of LC-MS analysis, two group
of cyclic peptides, nostoweipeptins and nostopeptolides were identified from two
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cyanobacteria strains, Nostoc sp.  XPORK  5A  and Nostoc sp. UK2aImI,
respectively (Figure 16).
In cyanobacteria, the nostopeptolide was first identified by Golakoti et al. (2000).
By comparing nostopeptolide A with the new nostopeptolide L1 discovered in this
study (Figures 16 and 17) it is apparent that nostopeptolide A contains more
proteinogenic amino acids, while more non-proteinogenic amino acids appear in
nostopeptolide L1. In addition, two different proline derivatives, 4-mPro and 4-
OH-Pro, were found in nostopeptolide L1. Unluckily, the nostopeptolide A was not
checked for protection of hepatocytes from apoptosis during the discovery, so it is
difficult to compare these two compounds from the aspect of biological function
and structure.
Figure 16. The chemical structures of nostoweipeptin W1 from Nostoc sp. XPORK
5A and nostopeptolides L1-L4 from Nostoc sp. UK2aImI.
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The nostocyclopeptide M1 (Figure 17) was the first identified bioactive cyclic
peptide with 4-mPro which inhibits apoptosis of hepatocytes caused by hepatotoxin
microcystin by blocking the anion transporters OATP1B1/1B3 (Jokela et al. 2010).
When nostocyclopeptin M1 was compared to nostopeptolides L and
nostoweipeptins, the only similarity was that all of these three compounds have a
ring  structure  with  a  side  chain  and  4-mPro.  Herfindal  et  al.  (2011) synthesized a
analogue of M1, which is only composed of L proteinogenic amino acids. The new
moleculehad lower bioactivity than M1 (Herfindal et al. 2011). It suggested the 4-
mPro  might  play  an  important  role  in  the  blocking  of  ion  transporters  OATP1B3
and OATP1B1.
Nostoweipeptins are different from the nostocyclopeptide M1, nostopeptolide A
and nostopeptolide L1-L4 peptides with 4-mPro. Nostoweipeptins contain two 4-
mPro and two 4-OH-Pro. It indicates that the biosynthesis of nostoweipeptins
differs from the others.
Figure 17. The chemical structures of nostocycleopeptin M1 and nostopeptolide A
(Golakoti et al. 2000; Jokela et al. 2010)
OATP1B1 and OATP1B3 are human organic anion transporters, which are
responsible for transport of many endobiotics and drugs. They were confirmed to
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deliver the hepatotoxin, microcystin/nodularin, into hepatocytes in order to cause
apoptosis of hepatocytes (Fischer et al. 2005). Here, nostopeptolide L and
nostoweipeptins were screened for their inhibition on OATP1B1/1B3 (Figure 18).
Among five cyclic peptides, nostoweipeptins show the greatest inhibition on
OATP1B3, while nostopeptolide L2 is the best inhibitor on OATP1B1. The
difference  on  bioactivities  of  cyclic  peptides  shows  their  different  binding
specificity on the organic anion transporters. To study the relationship between
structure and activity in these cyclic peptides could help us to find good selective
inhibitors on organic transporters OATP1B1 and OATP1B3.
Figure 18. 4-mPro-containing nostopeptolides (Np) L1-L4 and nostoweipeptin
(Nwp) W1 inhibit OATP1B1/1B3 mediated transport of nodularin (Nod) into
transfected HEK293T cells. A: Fluorescent images of cells co-transfected with
GFP and either OATP1B1 or OATP1B3. Note the round appearance and polarized
blebbing  of  Nod-treated  cells  compared  to  control.  Np  L2  and  Nwp  W1  show
complete protection whereas Np L3 and Np L1 have intermediate protection and
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the cells were pro-apoptotic. B: HEK293T cells transfected with OATP1B1 or 1B3
were treated with increasing concentrations of peptides before addition of Nod and
further incubations as in A. IC50 values were determined based on the ratio of green
fluorescence protein-positive cells with apoptotic or normal morphology. The data
are average of three independent experiments and scanning electron microscope.
The curves are based on the IC50 values from the regression analyses.
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5. Conclusion and Prospects
Of 40 benthic and lichen symbiotic cyanobacteria strains were studied for new anti-
AML compounds.  Half  of  them contained  anti-leukemia  activity.  Two new kinds
of  anti-leukemia  compounds,  which  are  new  variants  of  hassallidins  and
scytophycins, were identified. This study improved screening reliability of anti-
cancer compound from cyanobacteria by excluding the interference of microcystins
and adenosine. The marine cyanobacteria showed much more potential than lichen-
symbiotic cyanobacteria to find new anti-AML activity.
A new pair of trypsin inhibitors, nostosinA/B, were identified from Nostoc sp. FSN.
The computer docking showed that nostosin A binds to trypsin with a similar pose
like commercial trypsin inhibitor leupeptin. This is the first time to find potent
trypsin inhibitor with three residues from cyanobacteria. It not only revealed a new
trypsin inhibitor, but also gave a further insight of how trypsin enzyme interacts
with compact linear inhibitors. The nostosins could be used as a drug leads to test
their bioactivity on human disease experiment in vitro.  Their  structures  could  be
still optimized to improve their stability and activity with organic synthesis
methods.
Pseudoaeruginosins are linear tetrapeptides, which were identified as potent trypsin
inhibitors from N. spumigena collected from  Baltic  Sea.  The  biosynthesis  of
pseudoaeruginosins was revealed as a joint work of aeruginosin biosynthesis
pathway and methylproline biosynthesis genes in spumigin gene cluster. This study
demonstrated that NRPS pathway in cyanobacteria could use the enzymes in
another NRPS pathway to produce more diverse secondary metabolites. It also
exhibits a new way to synthesize antibiotics or drug leads with combined
biosynthesis.
4-mPro was once considered a rare non-proteinogenic amino acid. In this study,
eight 4-mPro-containing gene clusters were found in NCBI publicly available
genome database, and 12 good producers of 4-mPro amino acid were found when
116 cyanobacteria were screened by LC-MS. Two new groups of cyclic peptides
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with 4-mPro, nostopeptolides and nostoweipeptins, were identified as antitoxin
against hepatocyte apoptosis induced by microcystin by blocking anion transporters
OATP1B1/B3. The study of the genes coding for enzymes assembling the
nonproteinogenic amino acids are needed to reveal details of their biosynthesis and
possible biotechnological utilization of the enzymes in future. The additional
studies are needed to understand how the new compounds block anion transporter
OATP1B1/B3 and the role of 4-mPro in this process.
Nowadays, there is no doubt that antibiotic resistance and chemotherapy resistance
have  result  in  the  loss  of  many  useful  medicines  in  the  disease  treatment.  It  is
urgent to find new drugs to fulfill the need of patients. In this research, several
bioactive compounds were identified. It was shown that cyanobacteria are good
candidates to find novel compounds or drug leads. However, the bioassay was
performed in vitro, so it is not clear whether they will function in vivo or be stable
in the human metabolism. The new compounds could be evaluated in animal
models. Since the natural products usually are relatively large and not each subunit
play vital role in keeping the bioactivity, their structures could be optimized with
organic synthesis methods combined with bioassays as a guide. In addition, the
biosynthesis of these new identified compounds could be studied in the future. It
not only lead us to have a deep insight how cyanobacteria synthesis secondary
metabolites, but also provide some ideas for produce new compounds with
synthetic biology.
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